title: Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.
abstract: A polymer ultrasound contrast agent (UCA) developed in our lab has been shown to greatly reduce in size when exposed to ultrasound, resulting in nanoparticles less than 400 nm in diameter capable of escaping the leaky vasculature of a tumor to provide a sustained release of drug. Previous studies with the hydrophilic drug doxorubicin (DOX) demonstrated enhanced drug delivery to tumors when triggered with ultrasound. However the therapeutic potential has been limited due to the relatively low payload of DOX. This study compares the effects of loading the hydrophobic drug paclitaxel (PTX) on the agent's acoustic properties, drug payload, tumoricidal activity, and the ability to deliver drugs through 400 nm pores. A maximum payload of 129.46 ± 1.80 μg PTX/mg UCA (encapsulation efficiency 71.92 ± 0.99%) was achieved, 20 times greater than the maximum payload of DOX (6.2 μg/mg), while maintaining the acoustic properties. In vitro, the tumoricidal activity of paclitaxel loaded UCA exposed to ultrasound was significantly greater than controls not exposed to ultrasound (p<0.0016). This study has shown that PTX loaded UCA triggered with focused ultrasound have the potential to provide a targeted and sustained delivery of drug to tumors.
authors: School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA 19104, United States.
authors: Michael C
authors: MC
authors: Cochran
authors: John
authors: J
authors: Eisenbrey
authors: Richard O
authors: RO
authors: Ouma
authors: Michael
authors: M
authors: Soulen
authors: Margaret A
authors: MA
authors: Wheatley
references: Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47
references: 12628320
references: J Control Release. 2003 Jan 9;86(1):33-48
references: 12490371
references: Adv Drug Deliv Rev. 2008 May 22;60(8):886-98
references: 18374448
references: Int J Pharm. 2004 Nov 22;286(1-2):147-56
references: 15501011
references: Annu Rev Biomed Eng. 2007;9:415-47
references: 17651012
references: Ultrasound Med Biol. 2006 Nov;32(11):1771-80
references: 17112963
references: Int J Pharm. 2002 Mar 20;235(1-2):179-92
references: 11879753
references: Acc Chem Res. 2009 Jul 21;42(7):881-92
references: 19552457
references: Curr Oncol Rep. 2007 Jan;9(1):22-30
references: 17164044
references: J Clin Oncol. 1994 Sep;12(9):1748-53
references: 7916038
references: Adv Drug Deliv Rev. 2008 Jun 30;60(10):1097-102
references: 18479775
references: Comp Biochem Physiol C Toxicol Pharmacol. 2000 Jan;125(1):121-31
references: 11790336
references: J Control Release. 2010 Nov 20;148(1):13-17
references: 20691227
references: Cancer Chemother Pharmacol. 1998;42(3):177-82
references: 9685052
references: J Control Release. 2000 Mar 1;65(1-2):271-84
references: 10699287
references: J Biomed Mater Res A. 2003 Aug 1;66(2):347-55
references: 12889005
references: Ann Oncol. 2006 Aug;17(8):1263-8
references: 16740598
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
references: 20441782
references: Proc Natl Acad Sci U S A. 1989 Oct;86(20):7663-6
references: 2813349
references: Circulation. 1998 Sep 29;98(13):1264-7
references: 9751673
references: J Control Release. 2009 May 21;136(1):21-9
references: 19331851
references: IEEE Trans Biomed Eng. 2010 Jan;57(1):24-8
references: 19709952
references: Clin Cancer Res. 2002 May;8(5):1038-44
references: 12006516
references: Biochem Biophys Res Commun. 1999 Sep 24;263(2):398-404
references: 10491305
references: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
references: 9539785
references: Circ Res. 2009 Mar 13;104(5):679-87
references: 19168443
references: Int J Clin Oncol. 2001 Feb;6(1):55-8
references: 11706529
references: Ultrasonics. 2009 Dec;49(8):628-33
references: 19394992
references: Invest Radiol. 2000 Nov;35(11):661-71
references: 11110302
references: J Biomed Mater Res A. 2004 Jan 1;68(1):71-8
references: 14661251
references: J Control Release. 2006 May 15;112(2):149-55
references: 16556469
references: Pharm Res. 2008 Aug;25(8):1925-35
references: 18509603
references: J Control Release. 2010 Apr 2;143(1):2-12
references: 19925835
references: J Control Release. 2010 Apr 2;143(1):38-44
references: 20060024
references: Mol Ther. 2010 Jan;18(1):101-8
references: 19623162
references: Pharm Res. 2005 Dec;22(12):2079-90
references: 16132339
references: J Pharm Sci. 1997 Dec;86(12):1458-63
references: 9423162
references: Cancer Res. 2000 Aug 15;60(16):4440-5
references: 10969790
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: N Engl J Med. 1995 Apr 13;332(15):1004-14
references: 7885406
references: Eur J Cancer. 2001 Sep;37(13):1590-8
references: 11527683
references: Br J Cancer. 2005 Apr 11;92(7):1240-6
references: 15785749
references: Pharm Res. 1998 Jan;15(1):122-7
references: 9487558
references: Am J Pathol. 1995 May;146(5):1029-39
references: 7538264
references: J Control Release. 2006 Mar 10;111(1-2):128-34
references: 16380187
references: J Clin Oncol. 1990 Jul;8(7):1263-8
references: 1972736
references: Int J Nanomedicine. 2009;4:99-105
references: 19516888
references: Ultrasound Med Biol. 2004 Sep;30(9):1255-8
references: 15550330